M&A / Deals Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout BioPharma DiveThe deal secures two sleep disorder drugs that would fill a hole in the company s portfolio and intensify a competition with Takeda and Eisai.M&A / DealsNeuroscienceRead full story pharminent March 31, 2026 (Last updated: April 1, 2026) BioPharma Dive The deal secures two sleep disorder drugs that would fill a hole in the company s portfolio and intensify a competition with Takeda and Eisai. M&A / DealsNeuroscienceRead full story Post navigation Previous: Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis BuyNext: Novo hits back at rivals with cut-price Wegovy subscriptions Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
